Clinical Trial Update: Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing everolimus plus best supportive care to placebo plus best supportive care in patients with advanced neuroendocrine tumors of GI or lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Neuroendocrine Tumor of Gi Origin
• Neuroendocrine Tumor of Lung Origin

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced NET of GI Origin, Advanced NET of Lung Origin | Phase 3 | Status: COMPLETED | Results posted: 2016-12-28